Breast cancer is a highly aggressive cancer in females. Metastasis is a major obstacle to the efficient andsuccessful treatment of breast cancer. Cetyltrimethylammonium bromide (CTAB) has anti-tumor effects on a varie...Breast cancer is a highly aggressive cancer in females. Metastasis is a major obstacle to the efficient andsuccessful treatment of breast cancer. Cetyltrimethylammonium bromide (CTAB) has anti-tumor effects on a varietyof tumors. We showed that CTAB inhibits the metastasis of breast cancer to the lungs both in vitro and in vivo.Epithelial-mesenchymal transition (EMT) is thought to be one of the major processes mediating breast cancermetastasis. We found that CTAB suppressed EMT and regulated the levels of the classical EMT markers E-cadherin,N-cadherin, vimentin, Snail and Twist1. Moreover, as a candidate anti-tumor agent, CTAB showed primary safety invivo. Taken together, our results suggest that CTAB inhibits the migration of primary breast cancer to the lungs. Ourfindings confirm the clinical potential of CTAB for the treatment of breast cancer by targeting EMT. CTAB may thusbe a promising novel anti-tumor drug for the treatment of breast cancer metastasis.展开更多
基金This research was supported by 81803024(National Natural Science Foundation of China)DUT21LK23(Fundamental Research Funds for the Central Universities).
文摘Breast cancer is a highly aggressive cancer in females. Metastasis is a major obstacle to the efficient andsuccessful treatment of breast cancer. Cetyltrimethylammonium bromide (CTAB) has anti-tumor effects on a varietyof tumors. We showed that CTAB inhibits the metastasis of breast cancer to the lungs both in vitro and in vivo.Epithelial-mesenchymal transition (EMT) is thought to be one of the major processes mediating breast cancermetastasis. We found that CTAB suppressed EMT and regulated the levels of the classical EMT markers E-cadherin,N-cadherin, vimentin, Snail and Twist1. Moreover, as a candidate anti-tumor agent, CTAB showed primary safety invivo. Taken together, our results suggest that CTAB inhibits the migration of primary breast cancer to the lungs. Ourfindings confirm the clinical potential of CTAB for the treatment of breast cancer by targeting EMT. CTAB may thusbe a promising novel anti-tumor drug for the treatment of breast cancer metastasis.
